La Jolla Pharmaceutical Co. (NASDAQ:LJPC) fell 3.2% on Thursday . The company traded as low as $17.94 and last traded at $17.97, with a volume of 84,635 shares trading hands. The stock had previously closed at $18.57.

Several equities research analysts have recently commented on the company. Zacks Investment Research lowered La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, June 15th. Lake Street Capital assumed coverage on La Jolla Pharmaceutical in a research note on Tuesday, May 24th. They issued a “buy” rating and a $25.00 price objective for the company. Jefferies Group restated a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 8th. Finally, SunTrust Banks Inc. assumed coverage on La Jolla Pharmaceutical in a research note on Wednesday, June 22nd. They issued a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $39.50.

The stock’s market capitalization is $336.60 million. The firm has a 50-day moving average of $16.77 and a 200 day moving average of $17.55.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.22. On average, analysts expect that La Jolla Pharmaceutical Co. will post ($3.99) earnings per share for the current fiscal year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.